Betaine and Peroxisome Biogenesis Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

January 31, 2015

Study Completion Date

June 30, 2015

Conditions
Peroxisome Biogenesis Disorders
Interventions
DRUG

Betaine

"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:~* 6 g/day in children \< 30 kg, in 3 divided doses (2 g at meal time)~* 12 g/day in children \> 30 kg, in 4 divided doses (3 g at meal time and bed time)."

Trial Locations (1)

H3H 1P3

Montreal Children's Hospital, Montreal

All Listed Sponsors
collaborator

Children's Hospital and Medical Center, Omaha, Nebraska

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER

NCT01838941 - Betaine and Peroxisome Biogenesis Disorders | Biotech Hunter | Biotech Hunter